REGAIN CONTROL OVER OPIATE DEPENDENCE

Introducing the first prescription digital therapy designed to treat Opiate Dependence

reSETTM: FOR OPIATE DEPENDENCE

Pear Therapeutics has developed reSETTM, a mobile medical application, to be used in conjunction with outpatient therapy for treating Opiate Dependence

reSETTM is comprised of a patient-facing smartphone application and a clinician-facing web interface

reSETTM is comprised of a patient-facing smartphone application and a clinician-facing web interface

eFORMULATIONSTM AS A TREATMENT TOOL FOR OPIATE DEPENDENCE

reSETTM has the ability to improve abstinence and increase program retention when used in combination with pharmacotherapy,

  • Two studies with a total of 295 patients completing outpatient buprenorphine or methadone maintenance treatment for opiate dependence were randomized to receive standard treatment or reduced standard treatment with reSETTM.
  • Abstinence was measured through urine analysis and self-reporting.
  • Patients received either the current standard of care or reSETTM with limited clinician exposure.
  • In three separate randomized clinical trials involving 465 patients, reSETTM plus pharmacotherapy showed the ability to enhance abstinence, reduce drop-outs, and reduce required clinician intervention in Opiate Dependence.

Percent of Tested Weeks of Opioid Abstinence

Marsch et al. J Substance Abuse Treatment. 2014.

Mean Weeks of Continuous Opioid Abstinence

Bickel et al. Exp Clin Psychopharmacol. 2008.

Mean Weeks of Continuous Opioid Abstinence and Average Time Spent with Therapist

Bickel et al. Exp Clin Psychopharmacol. 2008.

SUBSTANCE USE DISORDER:  HIGH UNMET NEED, LIMITED ACCESS, AND FEW EVIDENCED-BASED TREATMENT OPTIONS  

  • Substance Use Disorder (SUD) is a chronic, relapsing disease, impacting more than 21.6 million Americans over the age of 12, and 39 million individuals worldwide.1
  • Every year, SUD results in over 200,000 deaths worldwide2, and the downstream consequences of SUD is estimated to cost society more than $400 billion.3
  • Only 11% of individuals with SUD in the US receive treatment4 due in part to a lack of access: more than 96% of US counties lack qualified clinicians to treat SUD.5
  • For patients who do receive care, there is significant variability in quality, frequency, and utilization of evidenced-based therapies across providers as well as discrepancies between research and real-world adherence to guidelines.6

reSETTM AS A TREATMENT TOOL FOR SUBSTANCE USE DISORDER

reSETTM has demonstrated improvement in both abstinence and program retention when used in conjunction with face-to-face therapy to treat SUD related to stimulants, marijuana, cocaine and alcohol

 

  • 507 patients with SUD across 10 treatment centers nation-wide were randomized to receive either face-to-face therapy, or a reduced amount of face-to-face therapy plus reSETTM.
  • Patients received 12 weeks of typical outpatient treatment with or without reSETTM (reSETTM was substituted for a portion of face-to-face therapy).

ABSTINENCE

  • Abstinence was measured twice weekly via urine analysis, breathalyzer, and self-reports.
  • In patients who were dependent on stimulants, marijuana, cocaine, or alcohol (n=395), 58.1% of patients receiving reSETTM were abstinent in study weeks 9-12, while 29.8% of patients receiving face-to-face therapy alone were abstinent during the same time frame (p<0.01).
  • Participants who tested positive for drug use at the start of the study (n=191), 26.7% of patients receiving reSETTM were abstinent in study weeks 9-12, while 3.2% of patients receiving traditional face-to-face therapy were abstinent during the same time frame (p<0.01).

All Patients

Graph-1

Patients Non-Abstinent at Baseline

Graph-2

RETENTION

  • Program retention is known to be a positive predictor of future, positive outcomes in SUD.
  • Patients receiving reSETTM showed statistically significant improvement in retention compared to face-to-face therapy alone.
ClinicalTrials.gov Identifier: NCT01104805

For more information, please contact us

Contact Us

*reSET not yet available for sale in the United States